Ranbaxy Laboratories, the Indian generics drugmaker, is considering acquiring production facilities either in the US or elsewhere that have already been approved by the US Food and Drug Administration, as it searches for ways to resolve the issues surrounding its import ban.

Malvinder Singh, Ranbaxy’s chief executive, said he aimed to “take products back to the US market at the earliest possible time.”